Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-cash Items (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Non-cash Items data on record, last reported at $13.2 million in Q4 2025.

  • For Q4 2025, Non-cash Items rose 509.85% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $13.2 million, up 509.85%, while the annual FY2025 figure was $13.2 million, 509.85% up from the prior year.
  • Non-cash Items reached $13.2 million in Q4 2025 per TNGX's latest filing, down from $14.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $51.4 billion in Q4 2021 and bottomed at $1.8 million in Q3 2021.
  • Average Non-cash Items over 5 years is $4.8 billion, with a median of $11.8 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: soared 674.84% in 2021, then tumbled 99.93% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $51.4 billion in 2021, then tumbled by 52.8% to $24.3 billion in 2022, then crashed by 99.74% to $62.6 million in 2023, then tumbled by 96.56% to $2.2 million in 2024, then surged by 509.85% to $13.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $13.2 million in Q4 2025, $14.7 million in Q3 2025, and $14.3 million in Q2 2025.